Ozempic and Mounjaro Back on Shelves

March 21, 2023

Novo Nordisk’s Ozempic and Eli Lilly’s Mounjaro, both diabetes drugs used off-label for weight loss, have been on a backlog for months due to an explosion of popularity. According to the US Food and Drug Administration, most doses of the two drugs are back in stock. This excludes the higher doses of Ozempic, however.

According to Fraiser Kansteiner, “Novo and Lilly’s new diabetes drugs have been at the center of a social media craze over their potential to help people lose weight. Illustrating the ubiquity of Ozempic’s off-label use, the drug even became the butt of a joke at the Oscars this year. Meanwhile, the Ozempic shortfall dovetailed with a paucity of Novo Nordisk’s approved obesity drug Wegovy last year. Wegovy—which is also girded by the semaglutide molecule, albeit at a higher dose—shook off its supply woes around the new year.”

To read more, click here.

(Source: Fierce Pharma, March 20th, 2023)

Share This Story!